Ignite Creation Date:
2024-05-05 @ 5:31 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00474786
Status:
COMPLETED
Last Update Posted:
2013-11-21
First Post:
2007-05-15
Brief Title:
Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
Sponsor:
Organization:
Pfizer